• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Chemoresistance and apoptotic pathway in ovarian cancer.

Research Project

Project/Area Number 10671539
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionTottori University School of Medicine

Principal Investigator

KANAMORI Yasunobu (1999-2000)  Tottori Univ.Dept.Obstet.Gynecol., Research Associates, 医学部, 助手 (70283984)

皆川 幸久 (1998)  鳥取大学, 医学部, 講師 (70190692)

Co-Investigator(Kenkyū-buntansha) TERAKAWA Naoki  Tottori Univ.Dept.Obstet.Gynecol., Professor, 医学部, 教授 (90163906)
KIGAWA Junzo  Tottori Univ.Dept.Obstet.Gynecol., Assistant Professor, 医学部, 助教授 (00177784)
金森 康展  鳥取大学, 医学部, 助手 (70283984)
Project Period (FY) 1998 – 2000
Project Status Completed (Fiscal Year 2000)
Budget Amount *help
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2000: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1999: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1998: ¥1,700,000 (Direct Cost: ¥1,700,000)
KeywordsOvarian cancer / Apoptosis / Chemosensitivity / Cisplatin / p53
Research Abstract

1. The effect of p53 gene transduction to chemosensitivity.
(1) p53 gene transduction by the recombinant adenovirus vector (AxCAp53) suppressed the cell growth and increased chemosensitivity to CDDP in SK-OV-3 and HeLa cells without p53 function. In contrast, AxCAp53 transfection did not affect the cell growth and the chemosensitivity in CDDP-resistant HeLa (HeLa/CDDP) cells.(2) Chemosensitivity to paclitaxel (PTX) was not affected by AxCAp53 in SK-OV-3, HeLa and HeLa/CDDP cells.(3) In SCID mice implanted with SK-OV-3 cells, the combination treatment of AxCAp53 and CDDP significantly inhibited the tumor growth, and increased Bax expression in tumors.
2. Induction of apoptosis and action of apoptotic pathway by the combination treatment of AxCAp53 and CDDP.
(1) AxCAp53 transfection or exposure to CDDP produced DNA fragmentation in SK-OV-3 and HeLa cells. The combination treatment of AxCAp53 and CDDP enhanced DNA fragmentation and increased Bax expression in those cells. DNA fragmentation did not appear after AxCAp53 transfection or exposure to CDDP in HeLa/CDDP cells. The combination treatment of AxCAp53 and CDDP did not affect DNA fragmentation and Bax expression.(2) PTX-induced DNA fragmentation and Bax expression did not change after the combination treatment of AxCAp53 and PTX.
The present study suggests that CDDP-resistant cells have a phenotype that is resistant to p53-dependent and-independent apoptosis and that PTX may induce p53-independent apoptosis.

Report

(4 results)
  • 2000 Annual Research Report   Final Research Report Summary
  • 1999 Annual Research Report
  • 1998 Annual Research Report
  • Research Products

    (25 results)

All Other

All Publications (25 results)

  • [Publications] Kigawa Junzo: "Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer."Cancer. 82(4). 697-702 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Kigawa Junzo: "Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer."Clin Cancer Res.. 4(7). 1737-1741 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Kanamori Yasunobu: "A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells."Eur J Cancer. 34(11). 1802-1806 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Minagawa Yukihisa: "Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways."Jpn J Cancer Res.. 90(12). 1373-1379 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimada Muneaki: "Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts."Eur J Cancer. 36(14). 1869-1875 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Kigawa Junzo et al.: "Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer."Cancer.. 82(4). 697-702 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Kigawa Junzo et al.: "Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer."Clin Cancer Res.. 4(7). 1737-1741 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Kanamori Yasunobu et al.: "A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivityto cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells."Eur J Cancer. 34(11). 1802-1806 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Minagawa Yukihisa et al.: "Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and-independent pathways."Jpn J Cancer Res.. 90(12). 1373-1379 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimada Muneaki et at.: "Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts."Eur J Cancer. 36(14). 1869-1875 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Kigawa Junzo: "Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer."Cancer. 82・4. 697-702 (1998)

    • Related Report
      2000 Annual Research Report
  • [Publications] Oishi Tetsuro: "Alteration of telomerase activity associated with development and extension of epithelial ovarian cancer."Obstet Gynecol. 91・4. 568-571 (1998)

    • Related Report
      2000 Annual Research Report
  • [Publications] Kigawa Junzo: "Gamma-gluramyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer."Clin Cancer Res. 4・7. 1734-1741 (1998)

    • Related Report
      2000 Annual Research Report
  • [Publications] Okada Makoto: "Alterations of the p53 gene and p53 protein expression in epihtlial ovarian cancer before and after chemotherapy."Int J Clin Oncol. 3・4. 191-203 (1998)

    • Related Report
      2000 Annual Research Report
  • [Publications] Kanamori Yasunobu: "A newly developed adenovirus-mediated transfer of a wild-type p53 gene increase sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells."Eur J Cancer. 34・11. 1802-1806 (1998)

    • Related Report
      2000 Annual Research Report
  • [Publications] Kigawa Junzo: "Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer"Cancer. 82・4. 697-702 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] Oishi Tetsuro: "Alteration of telomerase activity associated with development and extension of epithelial ovarian cancer"Obstet Gynecol. 91・4. 568-571 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] Kigawa Junzo: "Gamma-gluramyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer"Clin Cancer Res. 4・7. 1734-1741 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] Okada Makoto: "Alterations of the p53 gene and p53 protein expression in epihtlial ovarian cancer before and after chemotherapy"Int J Clin Oncol. 3・4. 191-203 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] Kanamori Yasunobu: "A newly developed adenovirus-mediated transfer of a wild-type p53 gene increase sensitivity to cis-diamminedichloroplatinum(II)in p53-deleted ovarian cancer sells"Eur J Cancer. 34・11. 1802-1806 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] Kigawa Junzo: "Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer." Cancer. 82・4. 697-702 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Oishi Tetsuro: "Alteration of telomerase activity associated with development and extension of epithelial ovarian cancer." Obstet Gynecol. 91・4. 568-571 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Kigawa Junzo: "Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer." Clin Cancer Res. 4・7. 1734-1741 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Okada Makoto: "Alterations of the p53 gene an p53 protein expression in epithelial ovarian cancer before and after chemotherapy." Int J Clin Oncol. 3・4. 191-203 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Kanamori Yasunobu: "A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells." Eur J Cancer. 34・11. 1802-1806 (1998)

    • Related Report
      1998 Annual Research Report

URL: 

Published: 1998-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi